Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirbanibulin versus diclofenac for actinic keratosis: long-term SCC incidence and safety study
2024-514394-22-00Phase 4Authorised
- Sponsor
- Almirall
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 4, randomised, single-blind trial in actinic keratosis (AK) comparing Klisyri arm with Solaraze arm (2 arms). Primary endpoint: Incidence of invasive squamous cell carcinoma. Planned start Jul 2024; status: authorised.
02
Drugs
tirbanibulindiclofenac
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2024-514394-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514394-22-00.